Developing a long-lasting injectable treatment for substance use disorder.
Surmounting substance use disorder using an ultra-long acting injectable platform.
This study is working on a new kind of long-lasting injection to help people with substance use disorder, making it easier and more convenient for them to stick to their treatment without needing surgery.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10831476 on NIH RePORTER |
What this research studies
This research focuses on creating an ultra-long-acting injectable treatment for substance use disorder (SUD), which is a chronic condition requiring long-term medication. The approach involves engineering a new type of injectable depot that can deliver medications like buprenorphine and naltrexone over an extended period without the need for surgical insertion. By improving the pharmacokinetics and reducing the risk of side effects associated with current treatments, this research aims to enhance patient adherence and outcomes. Patients will benefit from a more effective and convenient treatment option that addresses the challenges of existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with substance use disorder who require long-term pharmacotherapy.
Not a fit: Patients who are not diagnosed with substance use disorder or those who do not require medication for their condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and convenient treatment option for managing substance use disorder.
How similar studies have performed: Previous research has shown promise in developing long-acting injectables for substance use disorder, but this approach aims to address significant limitations of existing therapies, making it a novel endeavor.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Joshi, Nitin — Brigham and Women's Hospital
- Study coordinator: Joshi, Nitin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.